leisure time -WSS

leisure time

author：explore 2025-08-23 10:39:36 - browse：53

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： HIV vaccine remains elusive. Immunologists keep trying new ideas

hotspot

explore

WSS

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Global cancer cases to surge 77% by 2050, WHO report says

Adopting new red light myopia treatments may be short

It's time to retire 'poor historian' from clinicians' vocabularies

Padmanee Sharma of MD Anderson at center of lawsuit over credit

AstraZeneca stays mum on Medicare drug pricing negotiations

focus

leisure time

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Cancer drug shortages should be causing more outrage

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Virginia high school admissions case could be legal follow

The CDC's new social media misinformation war

Hollywood unions extend contract negotiations for actors

Case highlights the risks of experimental stem cell therapy

Medical records are filled with copy

Why CTE doesn’t keep Americans from enjoying the Super Bowl

knowledge

Devoted Health’s losses in Medicare Advantage persist

Why Novartis is going to walk from its acquisition of MorphoSys

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Readers respond to H5N1 and livestock movements, and more

A single Democrat is willing to weaken Medicare negotiation power

Top private equity targets in 2023: cardiology, clinical trials, lasers

hotspot

knowledge

explore

hotspot